EUCTR2012-000671-16-CZ进行中（未招募）不适用
A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities - AlePrevent
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 19,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adult patients, >/= 40 years of age
- •Prior Cardiovascular event, Coronary, Cerebrovascular or Perhipheral Arterial Disease
- •Established Diabetes Mellitus Type 2 or Hba1c>/=5.7%
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 570
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 280
排除标准
- •Concomitant treatment with a thiazolidinedione and/or fibrate
- •Triglycerides >500 mg/dL
- •Estimated glomerular filtration rate <30mL/min/1.73m2
- •Symptomatic congestive heart failure classified as NYHA class II-IV
- •Hospitalisation for congestive heart failure in last year
研究者
相似试验
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose AbnormalitiesEUCTR2012-000671-16-PLF. Hoffmann-La Roche Ltd19,000
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose Abnormalities- Stable Cardiovascular Disease and- Diabetes Mellitus Type 2 or Pre-diabetesMedDRA version: 15.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 15.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849MedDRA version: 15.1Level: LLTClassification code 10036481Term: Pre-diabetesSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-000671-16-LVF. Hoffmann-La Roche Ltd19,000
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose AbnormalitiesEUCTR2012-000671-16-ATF. Hoffmann-La Roche Ltd19,000
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose AbnormalitiesEUCTR2012-000671-16-GBF. Hoffmann-La Roche Ltd19,000
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose Abnormalities- Stable Cardiovascular Disease and- Diabetes Mellitus Type 2 or Pre-diabetesMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10036481Term: Pre-diabetesSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-000671-16-LTF. Hoffmann-La Roche Ltd19,000